Stock Events

Stock Events

Alaunos Therapeutics 

$3.07
32
+$0.21+7.34% Today

Statistics

Day High
3.14
Day Low
2.87
52W High
6.2
52W Low
1.67
Volume
12,298
Avg. Volume
20,303
Mkt Cap
6.85M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-6.44
-5.52
-4.6
-3.69
Expected EPS
N/A
Actual EPS
N/A

Financials

-46,790%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
20,000Revenue
-9.36MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TCRT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. has a strong presence in cell therapy for cancer, competing in the same space as Alaunos with its Yescarta and other cellular therapies.
Novartis
NVS
Mkt Cap237.61B
Novartis AG has been a pioneer in CAR-T cell therapy for cancer, competing in the broader market of advanced cancer therapies alongside Alaunos.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. has investments in cancer therapy, including CAR-T and potentially TCR-like therapies, making it a competitor in the oncology space.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is heavily involved in cancer treatment through immunotherapy and could potentially expand into TCR therapies, competing with Alaunos.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb Company has a broad portfolio in oncology, including cell therapies, which could compete with Alaunos's TCR approaches.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Janssen subsidiary, is investing in cancer therapies, including cell therapy, posing potential competition to Alaunos.

About

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Show more...
CEO
Mr. Holger Weis CPA
Employees
1
Country
US
ISIN
US98973P3091

Listings

XNAS
US
TCRT
BOATS
BOATS
TCRT.BOATS

0 Comments

Share your thoughts

FAQ

What is Alaunos Therapeutics stock price today?▼
The current price of TCRT is $3.07 USD — it has increased by +7.34% in the past 24 hours. Watch Alaunos Therapeutics stock price performance more closely on the chart.
What is Alaunos Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Alaunos Therapeutics stocks are traded under the ticker TCRT.
Is Alaunos Therapeutics stock price growing?▼
TCRT stock has risen by +0.83% compared to the previous week, the month change is a -4.86% fall, over the last year Alaunos Therapeutics has showed a +40.51% increase.
What is Alaunos Therapeutics market cap?▼
Today Alaunos Therapeutics has the market capitalization of 6.85M
When is the next Alaunos Therapeutics earnings date?▼
Alaunos Therapeutics is going to release the next earnings report on May 13, 2026.
What is Alaunos Therapeutics revenue for the last year?▼
Alaunos Therapeutics revenue for the last year amounts to 20,000 USD.
What is Alaunos Therapeutics net income for the last year?▼
TCRT net income for the last year is -9.36M USD.
How many employees does Alaunos Therapeutics have?▼
As of April 01, 2026, the company has 1 employees.
In which sector is Alaunos Therapeutics located?▼
Alaunos Therapeutics operates in the Health Care sector.
When did Alaunos Therapeutics complete a stock split?▼
The last stock split for Alaunos Therapeutics was on July 18, 2024 with a ratio of 1:10.
Where is Alaunos Therapeutics headquartered?▼
Alaunos Therapeutics is headquartered in Houston, US.